VerbatimParliament, as it happens

Science: Research

Asked by Mr Angus MacDonaldLiberal DemocratDepartment for Science, Innovation and TechnologyTabled Answered 3 February 2026UIN 108569

The question

To ask the Secretary of State for Science, Innovation and Technology, what assessment he has made of the impact of pharmaceutical and medical device R&D site closures on the trends in the levels of UK’s scientific research capacity since 2010.

Answered by Kanishka Narayan

The Government has made no formal assessment of the impact of pharmaceutical and medical device R&D site closures on trends in the UK’s scientific research capacity since 2010.

The Government does monitor the health of the UK life sciences sector, including R&D performed by UK businesses. Office for National Statistics data shows £9.3 billion of pharmaceutical R&D was performed by UK businesses in 2024, accounting for almost 17% of all R&D undertaken by UK businesses.

We are actively working with industry to boost the UK’s competitiveness and significantly grow the volume of private sector R&D and manufacturing in the UK over the next decade. For instance, the up to £520 million Life Sciences Innovative Manufacturing Fund and the pilot £50m Transformational R&D Investment Fund, which are supporting companies like UCB to invest in innovative early manufacturing in the UK.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim